A systematic review and meta-analysis for human epidermal growth factor receptor 2 on upper tract urothelial carcinoma patients.

IF 2 4区医学 Q3 ONCOLOGY Tumori Pub Date : 2024-02-01 Epub Date: 2023-08-09 DOI:10.1177/03008916231186178

Jianjun Ye, Xinyang Liao, Yu Qiu, Qiang Wei, Yige Bao

{"title":"A systematic review and meta-analysis for human epidermal growth factor receptor 2 on upper tract urothelial carcinoma patients.","authors":"Jianjun Ye, Xinyang Liao, Yu Qiu, Qiang Wei, Yige Bao","doi":"10.1177/03008916231186178","DOIUrl":null,"url":null,"abstract":"Objective: The expression and significance of human epidermal growth factor receptor 2 (Her2) in upper tract urothelial carcinoma (UTUC) remains controversial. Thus, we aimed to systemically review the Her2 expression in UTUC patients and its relationship with pathological characters and clinical outcomes with meta-analysis.Materials and methods: A systematically computerized search in PubMed, Scopus, Embase and Cochrane was conducted. From a total of 454 related articles, 35 articles were finally reviewed and 16 papers were chosen for further analysis. Pathological characters included tumor stage, grade, lymph node metastasis (LNM) and lymphovascular invasion (LVI). The clinical outcomes included overall survival (OS), recurrence-free survival (RFS), cancer specific survival (CSS), metastatic-free survival (MFS) and progression-free survival (PFS). RevMan software was used for meta-analyses.Results: In total 16 studies from 1994 to 2020 were chosen, 14 studies used immunohistochemistry to assess the expression of Her2 and 5 studies used in situ hybridization, with a positive rate of 0 to 74.0% and 7.2 to 18.1%, respectively. Her2-positive was significantly associated with stage (pooled HR 1.86; 95 % CI 1.43-2.42), grade (pooled HR 2.81; 95 % CI 1.01-7.85) and LNM (pooled HR 1.93; 95 % CI 1.18-3.15). However, there was no statistically relationship between Her2-positive with LVI (pooled HR 1.48; 95 % CI 0.64-3.46) and RFS (pooled HR 1.41; 95 % CI 0.98-1.83).Conclusions: This review indicated that UTUC patients with Her2-positive tended to develop higher stage and grade tumors and LNM. The Her2 expression in UTUC patients deserves further investigation in the future.","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"25-33"},"PeriodicalIF":2.0000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tumori","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/03008916231186178","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/8/9 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: The expression and significance of human epidermal growth factor receptor 2 (Her2) in upper tract urothelial carcinoma (UTUC) remains controversial. Thus, we aimed to systemically review the Her2 expression in UTUC patients and its relationship with pathological characters and clinical outcomes with meta-analysis.

Materials and methods: A systematically computerized search in PubMed, Scopus, Embase and Cochrane was conducted. From a total of 454 related articles, 35 articles were finally reviewed and 16 papers were chosen for further analysis. Pathological characters included tumor stage, grade, lymph node metastasis (LNM) and lymphovascular invasion (LVI). The clinical outcomes included overall survival (OS), recurrence-free survival (RFS), cancer specific survival (CSS), metastatic-free survival (MFS) and progression-free survival (PFS). RevMan software was used for meta-analyses.

Results: In total 16 studies from 1994 to 2020 were chosen, 14 studies used immunohistochemistry to assess the expression of Her2 and 5 studies used in situ hybridization, with a positive rate of 0 to 74.0% and 7.2 to 18.1%, respectively. Her2-positive was significantly associated with stage (pooled HR 1.86; 95 % CI 1.43-2.42), grade (pooled HR 2.81; 95 % CI 1.01-7.85) and LNM (pooled HR 1.93; 95 % CI 1.18-3.15). However, there was no statistically relationship between Her2-positive with LVI (pooled HR 1.48; 95 % CI 0.64-3.46) and RFS (pooled HR 1.41; 95 % CI 0.98-1.83).

Conclusions: This review indicated that UTUC patients with Her2-positive tended to develop higher stage and grade tumors and LNM. The Her2 expression in UTUC patients deserves further investigation in the future.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

对上尿路尿道癌患者的人类表皮生长因子受体 2 进行系统回顾和荟萃分析。

目的：人表皮生长因子受体 2（Her2）在上尿路尿路上皮癌（UTUC）中的表达及其意义仍存在争议。因此，我们旨在通过荟萃分析系统回顾UTUC患者中Her2的表达及其与病理特征和临床结果的关系：我们在 PubMed、Scopus、Embase 和 Cochrane 中进行了系统的计算机检索。从总共 454 篇相关文章中，最终审阅了 35 篇，并选择了 16 篇进行进一步分析。病理特征包括肿瘤分期、分级、淋巴结转移（LNM）和淋巴管侵犯（LVI）。临床结果包括总生存期（OS）、无复发生存期（RFS）、特定癌症生存期（CSS）、无转移生存期（MFS）和无进展生存期（PFS）。采用RevMan软件进行荟萃分析：共选择了1994年至2020年的16项研究，其中14项研究采用免疫组化方法评估Her2的表达，5项研究采用原位杂交方法，阳性率分别为0%至74.0%和7.2%至18.1%。Her2阳性与分期（汇总HR 1.86; 95 % CI 1.43-2.42）、分级（汇总HR 2.81; 95 % CI 1.01-7.85）和LNM（汇总HR 1.93; 95 % CI 1.18-3.15）明显相关。然而，Her2阳性与LVI（汇总HR 1.48；95 % CI 0.64-3.46）和RFS（汇总HR 1.41；95 % CI 0.98-1.83）之间没有统计学关系：本综述表明，Her2阳性的UTUC患者倾向于发展为分期和分级更高的肿瘤和LNM。Her2在UTUC患者中的表达值得今后进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Tumori 医学-肿瘤学

CiteScore

3.50

自引率

0.00%

发文量

审稿时长

6 months

期刊介绍： Tumori Journal covers all aspects of cancer science and clinical practice with a strong focus on prevention, translational medicine and clinically relevant reports. We invite the publication of randomized trials and reports on large, consecutive patient series that investigate the real impact of new techniques, drugs and devices inday-to-day clinical practice.